Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
Group of patients using the same aromatase inhibitor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aromatase inhibitors | Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aromatase inhibitors | Other | non-interventional study |
|
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the quality of life of patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch) | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch) in terms of side effects | 2 years |
Not provided
Inclusion Criteria:
Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.
Patients who were informed about the study and accepted to participate.
Exclusion Criteria:
Patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.
Not provided
Not provided
Not provided
Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.
Patients who were informed about the study and accepted to participate.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Adana | 01330 | Turkey (Türkiye) | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Ankara |
| 06100 |
| Turkey (Türkiye) |
| Pfizer Investigational Site | Ankara | 06590 | Turkey (Türkiye) |
| Pfizer Investigational Site | Ankara | Turkey (Türkiye) |
| Pfizer Investigational Site | Bursa | Turkey (Türkiye) |
| Pfizer Investigational Site | Denizli | Turkey (Türkiye) |
| Pfizer Investigational Site | Edirne | Turkey (Türkiye) |
| Pfizer Investigational Site | Erzurum | Turkey (Türkiye) |
| Pfizer Investigational Site | Gaziantep | Turkey (Türkiye) |
| Pfizer Investigational Site | Istanbul | 34303 | Turkey (Türkiye) |
| Pfizer Investigational Site | Istanbul | Turkey (Türkiye) |
| Pfizer Investigational Site | Izmir | 35340 | Turkey (Türkiye) |
| Pfizer Investigational Site | Izmir | Turkey (Türkiye) |
| Pfizer Investigational Site | Kocaeli | Turkey (Türkiye) |
| Pfizer Investigational Site | Malatya | Turkey (Türkiye) |
| Pfizer Investigational Site | Trabzon | Turkey (Türkiye) |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D047072 | Aromatase Inhibitors |
| ID | Term |
|---|---|
| D065088 | Steroid Synthesis Inhibitors |
| D004791 | Enzyme Inhibitors |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D004965 | Estrogen Antagonists |
| D006727 | Hormone Antagonists |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D045505 | Physiological Effects of Drugs |
Not provided
Not provided